Trial Profile
Pilot Study of BB3 to Improve Renal Function in Patients With Signs and Symptoms of Significant Renal Injury After Kidney Transplantation From Donors After Cardiac Death
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2023
Price :
$35
*
At a glance
- Drugs Terevalefim (Primary)
- Indications Delayed graft function; Renal failure
- Focus Therapeutic Use
- Sponsors Angion Biomedica; Elicio Therapeutics
- 01 Jun 2023 According to an Elicio Therapeutics media release, Angion Biomedica merged with the Elicio Therapeutics and the combined company is called as Elicio Therapeutics.
- 05 May 2021 According to an Angion Biomedica media release, data were published in the scientific journal Transplantation.
- 07 Nov 2019 Results published in the Angion Biomedica Media Release.